Psoriatic Arthritis Therapeutics Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 9.94 Billion |
| Market Size (2029) | USD 13.33 Billion |
| CAGR (2024 - 2029) | 6.10 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Psoriatic Arthritis Therapeutics Market Analysis
The Psoriatic Arthritis Therapeutics Market size is estimated at USD 9.94 billion in 2024, and is expected to reach USD 13.33 billion by 2029, growing at a CAGR of 6.10% during the forecast period (2024-2029).
Factors such as the increasing prevalence of psoriatic arthritis associated with obesity and strong pipeline products are anticipated to boost the market's growth.
The increasing cases of psoriasis globally and the increasing demand for psoriasis drugs for treatment are major drivers of market growth. For instance, according to the study published in Rheumatology International in August 2023, the prevalence of psoriatic arthritis (PsA) at age 60 is expected to increase from 1% in 2019 to over 3% by 2050, with a more significant rise in women, reaching approximately 3.5%. Such a rise in psoriatic arthritis would increase the adoption of its treatments, driving market growth.
According to the study published in UpToDate Journal in April 2024, psoriatic arthritis (PsA) affects both genders equally, with an annual incidence of approximately 6 cases per 100,000 individuals and a prevalence of about 1 to 2 cases per 1,000 in the general population. Therefore, the high annual incidence is anticipated to increase the demand for psoriatic arthritis treatments, boosting market growth.
In addition, the development of new therapeutic methods, such as novel drugs with oral administration, is expected to drive market growth. For example, in November 2022, Janssen Pharmaceutical Companies of Johnson & Johnson launched a new posthoc analysis of the Phase 3 DISCOVER program evaluating TREMFYA (guselkumab) in adult patients with active psoriatic arthritis.
The results showed that early skin and enthesitis responses predicted longer-term clinical responses, including disease remission, at week 52. Additionally, regulatory authorities approving new drugs, such as AbbVie's SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor for treating adults with active psoriatic arthritis, are contributing to market growth.
Factors such as the rising incidence of psoriatic arthritis and companies increasingly developing psoriatic arthritis drugs are expected to contribute to market growth. However, the high cost of treatment is expected to hamper market growth.
Psoriatic Arthritis Therapeutics Market Trends
The Immunosuppressants Segment is Expected to Hold a Significant Market Share
Immunosuppressants are expected to experience the fastest growth in the psoriasis drugs market during the forecast period. This is due to several factors, including their improved safety and efficacy compared to other drug classes, which have led to increased patient adoption.
Major approved antibodies targeting interleukins, such as Taltz (ixekizumab), Cosentyx (secukinumab), Siliq (brodalumab), Tremfya (guselkumab), Ilumya (tildrakizumab), and SKYRIZI (risankizumab), aid in the adoption of immunosuppressants among the patient population.
In September 2022, the US Food and Drug Administration (USFDA) approved Deucravacitinib, an oral selective tyrosine kinase 2 (TYK2) inhibitor, for treating adults with moderate to severe plaque psoriasis eligible for systemic therapy or phototherapy. Furthermore, in August 2022, the US FDA greenlit ustekinumab (STELARA), which was the first and only biologic medication for treating active psoriatic arthritis (PsA) in pediatric patients aged 6 years and above. These regulatory nods are bolstering the segment's growth.
According to data from PubMed published in December 2022, immunosuppressants used for the treatment of psoriatic arthritis were tolerable and safe, increasing the demand for these drugs in the market. Therefore, the safety and tolerability of immunosuppressants boost their adoption in the highly affected elderly population, thereby fostering segment expansion.
Therefore, the significance of immunosuppressants and new launches are expected to contribute to market growth during the forecast period.
North America is Expected to Hold a Major Market Share During the Forecast Period
North America is projected to hold a major share of the psoriatic arthritis treatment market due to several factors. One of the primary reasons for this is the region's growing prevalence of psoriatic arthritis and obesity, which has increased awareness of the condition.
Furthermore, the advent of advanced therapies for psoriatic arthritis has led to an increase in adoption. For instance, according to the study published in the Journal of Rheumatology in May 2024, advanced therapies enhanced patient outcomes in psoriatic arthritis (PsA) in the Canadian population. Therefore, enhanced patient outcomes are anticipated to bolster market demand, driving market growth in the region.
Developed countries such as the United States and Canada have established healthcare systems that have a rapid adoption rate for new drugs, therapies, and technologies. As a result, expenditures on psoriatic arthritis therapeutics are expected to rise as the disease becomes more prevalent in the future.
Furthermore, rising initiatives from the key market players, such as partnerships for commercializing psoriatic therapies in the United States, are anticipated to propel market growth due to increased accessibility. For instance, in February 2024, Biocon Biologics, a subsidiary of Biocon, entered a significant settlement and licensing agreement with Janssen Biotech Inc. This agreement facilitates the commercialization of Bmab 1200, a proposed biosimilar to Stelara, in the United States for treating psoriasis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
Therefore, owing to the benefits associated with advanced psoriatic treatments and key initiatives by the market players, the North American market is expected to record rapid growth over the forecast period.
Psoriatic Arthritis Therapeutics Industry Overview
The psoriatic arthritis therapeutics market is semi-consolidated, with only a few key players operating. The majority of these key players involved in the research and development of psoriatic arthritis therapy drugs are located in developed countries. Established market leaders with greater funds for research and development and better distribution systems already have a strong foothold in the market. Some of the key players operating in the market include AbbVie Inc., Johnson & Johnson, Pfizer Inc., Sanofi SA, and Bristol-Myers Squibb.
Psoriatic Arthritis Therapeutics Market Leaders
-
AbbVie Inc
-
Johnson & Johnson
-
Pfizer Inc.
-
Sanofi S.A.
-
Bristol-Myers Squibb
*Disclaimer: Major Players sorted in no particular order
Psoriatic Arthritis Therapeutics Market News
- April 2024: The US Food and Drug Administration approved the SELARSDI (ustekinumab-aekn) injection, which Alvotech and Teva jointly developed. This approval designated SELARSDI as a biosimilar to Stelara, intended for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis.
- February 2024: The US Food and Drug Administration approved SIMLANDI (adalimumab-ryvk) injection developed by Alvotech and Teva. This approval classified SIMLANDI as an interchangeable biosimilar to Humira, intended for the treatment of various conditions, including adult rheumatoid arthritis, juvenile idiopathic arthritis, and adult psoriatic arthritis.
Psoriatic Arthritis Therapeutics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Prevalence of Psoriatic Arthritis Associated with Increasing Obesity
- 4.2.2 Strong Product Pipeline
-
4.3 Market Restraints
- 4.3.1 High Cost of Treatment
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Drug Class
- 5.1.1 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- 5.1.2 Disease-Modifying Antirheumatic Drugs (DMARDs)
- 5.1.3 Immunosuppressants
- 5.1.4 Biologic Agents
- 5.1.5 Other Drug Classes
-
5.2 By Route of Administration
- 5.2.1 Oral
- 5.2.2 Parenteral
- 5.2.3 Other Routes of Administration
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Pfizer Inc.
- 6.1.2 Eisai Inc
- 6.1.3 UCB Biosciences Inc.
- 6.1.4 Sanofi SA
- 6.1.5 Otsuka Pharmaceutical
- 6.1.6 Sumitomo Dainippon Pharma Co.
- 6.1.7 Johnson & Johnson
- 6.1.8 Bristol-Myers Squibb
- 6.1.9 AbbVie Inc.
- 6.1.10 Alvotech
- 6.1.11 Teva Pharmaceuticals
- 6.1.12 Coherus BioSciences Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityPsoriatic Arthritis Therapeutics Industry Segmentation
As per the scope of the report, psoriatic arthritis is a form of arthritis that affects some people with psoriasis, a condition that develops red patches on the skin with silvery scales. Psoriatic arthritis therapeutics include drugs that help relieve pain, reduce inflammation, slow the progression of psoriatic arthritis, or directly target parts of the immune system that trigger inflammation.
The psoriatic arthritis treatment market is segmented by drug class, route of administration, and geography. By drug class, the market is segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), immunosuppressants, biologic agents, and others. By route of administration, the market is segmented into oral, parenteral, and others. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD) for all the above segments.
| By Drug Class | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | |
| Disease-Modifying Antirheumatic Drugs (DMARDs) | ||
| Immunosuppressants | ||
| Biologic Agents | ||
| Other Drug Classes | ||
| By Route of Administration | Oral | |
| Parenteral | ||
| Other Routes of Administration | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Psoriatic Arthritis Therapeutics Market Research FAQs
How big is the Psoriatic Arthritis Therapeutics Market?
The Psoriatic Arthritis Therapeutics Market size is expected to reach USD 9.94 billion in 2024 and grow at a CAGR of 6.10% to reach USD 13.33 billion by 2029.
What is the current Psoriatic Arthritis Therapeutics Market size?
In 2024, the Psoriatic Arthritis Therapeutics Market size is expected to reach USD 9.94 billion.
Who are the key players in Psoriatic Arthritis Therapeutics Market?
AbbVie Inc, Johnson & Johnson, Pfizer Inc., Sanofi S.A. and Bristol-Myers Squibb are the major companies operating in the Psoriatic Arthritis Therapeutics Market.
Which is the fastest growing region in Psoriatic Arthritis Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Psoriatic Arthritis Therapeutics Market?
In 2024, the North America accounts for the largest market share in Psoriatic Arthritis Therapeutics Market.
What years does this Psoriatic Arthritis Therapeutics Market cover, and what was the market size in 2023?
In 2023, the Psoriatic Arthritis Therapeutics Market size was estimated at USD 9.33 billion. The report covers the Psoriatic Arthritis Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Psoriatic Arthritis Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Psoriatic Arthritis Therapeutics Industry Report
Statistics for the 2024 Psoriatic Arthritis Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Psoriatic Arthritis Therapeutics analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
